Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study

Oswald, Ailsa J., Symeonides, Stefan N., Wheatley, Duncan, Chan, Stephen, Brunt, Adrian Murray, McAdam, Karen, Schmid, Peter, Waters, Simon, Poole, Christopher, Twelves, Chris, Perren, Timothy, Bartlett, John, Piper, Tammy, Chisholm, Eve Macdonald, Welsh, Michelle, Hill, Robert, Hopcroft, Lisa E. M., Barrett-Lee, Peter ORCID: and Cameron, David A. 2023. Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study. Breast Cancer Research and Treatment 199 (1) , pp. 35-46. 10.1007/s10549-023-06873-8

[thumbnail of BARRETT-LEE, PETER - Aromatase inhibition plusminus Src inhibitor saracatinib.pdf]
PDF - Published Version
Available under License Creative Commons Attribution.

Download (1MB) | Preview


Purpose The development of oestrogen resistance is a major challenge in managing hormone-sensitive metastatic breast cancer. Saracatinib (AZD0530), an oral Src kinase inhibitor, prevents oestrogen resistance in animal models and reduces osteoclast activity. We aimed to evaluate the efficacy of saracatinib addition to aromatase inhibitors (AI) in patients with hormone receptor-positive metastatic breast cancer. Methods This phase II multicentre double-blinded randomised trial allocated post-menopausal women to AI with either saracatinib or placebo (1:1 ratio). Patients were stratified into an “AI-sensitive/naïve” group who received anastrozole and “prior-AI” group who received exemestane. Primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate (ORR) and toxicity. Results 140 patients were randomised from 20 UK centres to saracatinib/AI (n = 69) or placebo/AI (n = 71). Saracatinib was not associated with an improved PFS (3.7 months v. 5.6 months placebo/AI) and did not reduce likelihood of bony progression. There was no benefit in OS or ORR. Effects were consistent in “AI-sensitive/naive” and “prior-AI” sub-groups. Saracatinib was well tolerated with dose reductions in 16% and the main side effects were gastrointestinal, hypophosphatemia and rash. Conclusion Saracatinib did not improve outcomes in post-menopausal women with metastatic breast cancer. There was no observed beneficial effect on bone metastases.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Publisher: Springer
ISSN: 0167-6806
Date of First Compliant Deposit: 26 January 2024
Date of Acceptance: 31 January 2024
Last Modified: 13 Feb 2024 11:00

Actions (repository staff only)

Edit Item Edit Item


Downloads per month over past year

View more statistics